NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests

NeoGenomics (NASDAQ:NEO) announced an expansion of its Immuno-Oncology profiling test menu.
As quoted in the press release:

The Company has expanded its NeoTYPE^® cancer profiles to include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing.
TMB is a new genomic biomarker that is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. Studies in lung, melanoma and bladder cancers showed that objective response to checkpoint immunotherapy was predicted by the presence of high TMB. TMB tests will be available on a standalone basis, and in combination with the various cancer-specific NeoTYPE® Profiles offered at NeoGenomics.
MSI testing is being added to our profiling in response to the FDA’s announcement⁽¹⁾ on May 23rd that Merck’s Keytruda drug was approved for the treatment of patients with metastatic solid tumors that have been identified as being MSI-high or mismatch repair deficient (MMR). NeoGenomics offers MSI and MMR testing as part of its comprehensive testing services.
Dr. Maher Albitar, the Company’s Senior Vice President, Chief Medical Officer and Director of Research and Development, commented, “Despite the significant success of checkpoint inhibitor immunotherapies, not all patients respond to therapy and there is a need to identify the subset of patients that are more likely to respond. NeoGenomics provides a broad range of cancer immuno-profiling tests, including TMB, MMR, MSI, and PD-L1 expression testing, to more precisely determine which patients are good candidates for immunotherapy. This immuno-profiling is combined with genomic profiling for comprehensive multimodality cancer profiling.”

Click here to read the full press release.